Diabetes Information

Diabetic Complications - Can Benfotiamine Help Prevent Them?


Diabetic complications contribute too many life threatening diseases globally. The root cause of diabetic complications is elevated glucose levels which contribute to blood vessel damage. Diabetic retinopathy, nephropathy, or neuropathy are caused by damage to small blood vessel in the eyes, nerves and kidneys, etc. The bottom line of this damage is the lowering of the life expectancy of millions of diabetics worldwide.

What Can Be Done About It?

Few therapies are available today that treat diabetic complications. Most healthcare professionals recommend that their patients monitor their blood sugar by taking several blood readings a day to determine the amount of sugar in their blood. Blood sugar readings are generally higher from one to two hours after a meal.

It is suggested by these professionals that keeping blood sugar readings as close to normal as possible will reduce the onset of diabetic complications. Research has shown that there are four, chemical pathways that lead to diabetic complications. Instead of trying to explain these rather difficult chemical pathways, let the reader understand that diabetic complications are mainly caused by excess sugar in the cells, a condition known by the term advanced glycation endproducts (AGE) formation.

The research that was released in 2003 by a team of researchers from the Albert Einstein Collage of Medicine opened the possibilities that it may be possible to actually prevent and/or contain diabetic complications such as retinopathy, neuropathy and heart/circulatory conditions brought about by the presence of advanced glycation endproducts.

What Did This Research Suggest?

The Einstein researchers' work showed that a substance called, "benfotiamine", could reduce the effects of AGE by increasing the amount of an enzyme called transketolase. The research indicated that transketolase was increased by 300% which was enough to make a serious reduction of three of the four chemical pathways that open the door for diabetic complications in terms of vascular damage in diabetics. This vascular damage is directly responsible for the diabetic complications such as neuropathy, retinopathy and heart/circulatory conditions that lead to heart attack and stroke.

Can Benfotaimine Be Considered A Prudent Preventative?

Current research suggests that benfotiamine could possibly reduce the chances of diabetics developing the aforementioned complications. Many healthcare professionals readily recommend patients to add this nutritional supplement to their toolkit in the battle to prevent these insidious conditions that shorten the lives of thousands of diabetics annually.

Where Can I Find More Information About Benfotiamine?

More information about benfotiamine can be found by visiting the web site below and following the links. These links will give the reader a good base to make an informed decision about the use of benfotiamine in the battle against diabetic complications brought about by the presence of advanced glycation endproducts (AGE) which is excess sugar in the blood.

Research:

Hans-Peter Hammes, Xueliang Du, Diane Edelstein, Tetsuya Taguchi, Takeshi Matsumura, Qida Ju, Jihong Lin, Angelika Bierhaus, Peter Nawroth, Dieter Hannak, Michael Neumaier, Regine Bergfeld, Ida Giardino, Michael Brownlee. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine 9, 294 - 299 (01 Mar 2003).

Michael Brownlee. Biochemistry and molecular cell biology of diabetic complications Nature 414, 813 - 820 (13 Dec 2001).

Roya Babaei-Jadidi, Nikolaos Karachalias, Naila Ahmed, Sinan Battah, Paul J. Thornalley. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine - Complications. Diabetes. (August 2003).

Zach Malott is CEO of Brentwood Health International, a nutritional supplement company involved in distribution and supplying wholesale, retail and end users.

Mr. Malott is available to discuss the research as it applies to benfotiamine in the treatment and prevention of diabetic complications such as neuropathy and retinopathy.

He can be reached at:

Phone: 505.354.0526

Website: http://www.emuhealthproducts.com


MORE RESOURCES:

MiamiHerald.com

Corporate Watch
Wall Street Journal
Despite clinical data suggesting a link between Seroquel and increased risk for diabetes, AstraZeneca's primary legal argument is that there is no evidence ...
AstraZeneca Wins Trial on Seroquel Diabetes ClaimBusinessWeek
AstraZeneca wins US liability case on SeroquelReuters
AstraZeneca wins 1st trial over alleged drug harmThe Associated Press
Drug Store News -ONN.tv -RTT News
all 163 news articles »


World News

Manage diabetes to preventing heart disease and stroke
The Morning Sun
By MIDMICHIGAN HEALTH Heart disease is common in people with diabetes, but the good news is that taking good care of diabetes and the body today can help ...
Right Knowledge and Conduct is the Key to Survive with DiabetesTopNews United States
Online, Phone Tests Assess Diabetes RiskBusinessWeek
Education, behavior key to living with diabetesNews-Herald.com
Medscape -UPI.com -About - News & Issues (blog)
all 112 news articles »



Quad-Cities Online

Health department home health staff note American Diabetes Alert Day
Quad-Cities Online
The Henry and Stark County Health Departments' Home Health Nursing staff announce that Tuesday, March 23rd has been proclaimed the American Diabetes Alert ...
Diabetes health fair Saturday -- at the cemeteryAustin American-Statesman (blog)
'Diabetes Alert Day' is March 23TriValley Central
"The silent killer"San Jose Mercury News
Medical News Today (press release) -Diabetes.co.uk -Marketwire (press release)
all 16 news articles »


India Talkies

Selenium Could Shield Against Diabetes
BusinessWeek
THURSDAY, March 18 (HealthDay News) -- Scientists have found evidence that older men with higher levels of selenium are less likely to suffer from ...
Dietary supplement can reduce diabetes risk – but only in menTelegraph.co.uk
Selenium may help fight diabetes in menTimes of India
Dietary Supplement Can Lower Risk of Diabetes Just in MenDiet.co.uk
eMaxHealth -Diabetes.co.uk -TopNews United States
all 31 news articles »


Daily Contributor

FDA Rejects Amylin Diabetes Drug, Seeks More Info
Wall Street Journal
NEW YORK (Dow Jones)--The US Food and Drug Administration denied approval of a long-acting version of diabetes drug ...
Diabetes Drug From Lilly, Amylin Under ScrutinyForbes
FDA asks for risk plan info on diabetes drugThe Associated Press
Alkermes, others rise on Byetta newsBoston Globe
BusinessWeek -Cincinnati.com -Xconomy
all 313 news articles »


Reuters

A Diagnosis of Pre-Diabetes Isn't Enough to Motivate Many Patients
Diabetes Health (press release)
In a study that tracked 1402 people with pre-diabetes, researchers found that only about half of them responded to the diagnosis by trying to shed weight or ...
Diabetes Mellitus - an increasing problemLiberty County Times
Blood exam predicts risk for diabetesPaducah Sun
Are You At Risk For Diabetes?NJ TODAY
Reuters -Gather.com -India Infoline.com
all 26 news articles »


Bristol combination diabetes drug under review
BusinessWeek
Onglyza, made by Bristol-Myers and AstraZeneca, is already approved as a diabetes treatment and metformin is a widely-used generic diabetes pill. ...
FDA Approves Another Type 2 Diabetes Drug ApplicationeMaxHealth
Bristol-Myers Squibb, AstraZeneca Say FDA Accepts NDA For An Onglyza ...RTT News
Market Report -- In Play (BMY)MSN Money
News-Medical.net -Drug Store News
all 22 news articles »


Studies: Drugs don't reduce heart problems for diabetes patients
USA Today
They involve people with Type 2 diabetes — the most common form and the one rising because of the obesity epidemic. Diabetics have more than double the risk ...

and more »


Has Roche Given Up On Diabetes Devices?
Forbes
Listening to O'Day speak one would never know that Roche is even in the business of diabetes devices. Granted this unit has struggled mightily over the past ...


Google News

home | site map
© 2006